Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore.

MLA

Leo, Yee Sin, et al. “Immunogenicity and Safety of Recombinant Tetravalent Dengue Vaccine (CYD-TDV) in Individuals Aged 2-45 y: Phase II Randomized Controlled Trial in Singapore.” Human Vaccines & Immunotherapeutics, vol. 8, no. 9, Sept. 2012, pp. 1259–71. EBSCOhost, https://doi.org/10.4161/hv.21224.

APA

Leo, Y. S., Wilder-Smith, A., Archuleta, S., Shek, L. P., Chong, C.-Y., Leong, H. N., Low, C. Y., Oh, M.-L. H., Bouckenooghe, A., Wartel, T. A., & Crevat, D. (2012). Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore. Human Vaccines & Immunotherapeutics, 8(9), 1259–1271. https://doi.org/10.4161/hv.21224

Chicago

Leo, Yee Sin, Anneliese Wilder-Smith, Sophia Archuleta, Lynette P Shek, Chia-Yin Chong, Hoe Nam Leong, Chian Yong Low, et al. 2012. “Immunogenicity and Safety of Recombinant Tetravalent Dengue Vaccine (CYD-TDV) in Individuals Aged 2-45 y: Phase II Randomized Controlled Trial in Singapore.” Human Vaccines & Immunotherapeutics 8 (9): 1259–71. doi:10.4161/hv.21224.